Study on Antidepressant Activity of Pseudo-Ginsenoside HQ on Depression-Like Behavior in Mice

Chen, Lixue; Zeng, Qi; Shao, Zonghong; Li, Shanshan; Qi, Yuli; Gao, Kun; Liu, Song-Xin; Li, Zhuo; Sun, Yinshi

doi:10.3390/molecules24050870

Cited by 19 publications

(12 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After screening with the set standards of OB ≥30% and DL ≥0.18, 33 potentially active ingredients were retrieved from TCMSP and TCMID, among which 7 were potential active ingredients of Hyacinth chrysoides, 11 were potential active ingredients of Panax quinquefolium, 4 were potential active ingredients of Acorus tatarinowii, and 15 were potential active ingredients of turmeric. Ginsenoside rh2 and its metabolites can reduce the activity duration of forced swimming test (FST) and tail suspension test (TST) in mice and improve the depression-like behavior induced by lipopolysaccharide (LPS), showing the highest antidepressant effect at 30 mg/kg [ 42 ]. Kaempferol alleviated hippocampal neuron injury in CUMS depression model rats by inhibiting autophagy and oxidative stress [ 43 ].…”

Section: Resultsmentioning

confidence: 99%

Therapeutic Targets and Mechanism of Xingpi Jieyu Decoction in Depression: A Network Pharmacology Study

Chang

Tian

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background. Depression is a common mental disease that lacks effective therapeutic drugs with good curative effects and few adverse reactions. Traditional Chinese medicine (TCM) has the advantages of multiple components, multiple channels, and fewer adverse reactions in the treatment of depression. Although Xingpi Jieyu Decoction (XPJYD) demonstrates a good therapeutic effect on depression, the pharmacological mechanism underlying its antidepressant effect is still unclear. Methods. We used a network pharmacology strategy, including the construction and analysis of a complex drug-disease network, to explore the complex mechanism of XPJYD treatment of depression. In addition, molecular docking technology was used to preliminarily study the binding ability of the potential active components and core therapeutic targets of XPJYD. Results. The network pharmacology results showed 42 targets of XPJYD that are involved in depression. PPI network analysis demonstrated that the top 10 core targets were AKT1, VEGFA, MAPK8, FOS, ESR1, NR3C1, IL6, HIF1A, NOS3, and AR. The molecular docking results showed that the binding energies of beta sitosterol with AR, FOS, AKT1, VEGFA, NR3C1, and NOS3 were less than −7.0 kcal·mol−1, indicating a good docking effect. The GO enrichment analysis results showed that the XPJYD antidepression mechanism mainly involves the following biological processes such as apoptotic signaling pathway, cellular response to lipid, inflammatory response, and others. The KEGG analysis results indicated that XPJYD may regulate 13 pathways such as PI3K-Akt signaling pathway and estrogen signaling pathway in the treatment of depression. Conclusions. This study reflects the characteristics of the mechanism of action by which XPJYD treats depression, which includes multiple components, multiple targets, and multiple pathways, and provides a biological basis for further verification and a novel perspective for drug discovery in depression.

show abstract

Section: Resultsmentioning

confidence: 99%

Therapeutic Targets and Mechanism of Xingpi Jieyu Decoction in Depression: A Network Pharmacology Study

Chang

Tian

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…Indeed, SIRT1 overexpression has shown significant neuroprotective effects, increasing the level of BDNF [158]. Also, Shen et al (2019) [159] and Chen et al (2019) [160] showed that BDNF and SIRT1-related pathway activation produced strong effects, similar to those obtained with classic antidepressants. According to various studies showing the ability of PPARγ agonists to induce the expression of BDNF [124], it is possible to propose a possible effect of drugs, such as RSG, in improving cognitive symptoms typical of schizophrenia.…”

Section: Pparγ In Schizophreniamentioning

confidence: 93%

PPARγ and Cognitive Performance

Castelli

Catanesi

Antonosante

et al. 2019

IJMS

View full text Add to dashboard Cite

Recent findings have led to the discovery of many signaling pathways that link nuclear receptors with human conditions, including mental decline and neurodegenerative diseases. PPARγ agonists have been indicated as neuroprotective agents, supporting synaptic plasticity and neurite outgrowth. For these reasons, many PPARγ ligands have been proposed for the improvement of cognitive performance in different pathological conditions. In this review, the research on this issue is extensively discussed.

show abstract

“…FST has been modified according to the documentary method [ 12 ]. In short, 1 h after administration, mice were placed in a Perspex bucket (height 25 cm, diameter 12 cm), filled with water to a height of 10 cm (water temperature was kept at 23 ± 2°C).…”

Section: Methodsmentioning

confidence: 99%

Liquiritin Alleviates Depression-Like Behavior in CUMS Mice by Inhibiting Oxidative Stress and NLRP3 Inflammasome in Hippocampus

Liu

Yuan

Zhang

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. Central inflammation is generally accepted to be involved in the pathology of depression. We investigated whether liquiritin exerts antidepressant effects by inhibiting central NLRP3 inflammasomes. Results. The behavioral despair model and chronic unpredictable mild stress (CUMS) model in mice were established to evaluate the antidepressant action of liquiritin. In the despair model study, liquiritin (40 mg/kg) administration reduced immobility time in tail suspension test (TST) and forced swimming test (FST) without affecting locomotion activity. In CUMS model study, liquiritin (40 mg/kg, once daily for 4 weeks) significantly increased sucrose consumption and body weight of CUMS mice. The behavioral experiment results showed that liquiritin reduced the immobile time of CUMS mice in TST and FST, respectively, and increased the time spent and open arm entries in the elevated plus-maze (EPM) test. Further, the hippocampal superoxide dismutase (SOD) activity was increased in liquiritin-treated group, while malonaldehyde (MDA) decreased. Additionally, the hippocampal cytokines interleukin-18 (IL-18) and interleukin-1 beta (IL-1β) contents were reduced in the liquiritin-treated group. Further, liquiritin downregulated the expression of NLRP3 in the hippocampus of CUMS mice rather than TLR4. Besides, NLRP3 inflammasome-associated proteins caspase-1 and ASC were also downregulated. However, liquiritin did not alter the thermal stability of NLRP3 in the cellular thermal shift assay (CETSA), suggesting that its inhibition of NLPR3 was not by direct targeting of NLRP3 protein. Conclusions. Liquiritin attenuates depression-like behavior of CUMS mice and inhibited cytokines levels triggered by NLRP3 inflammasome, suggesting the antidepressant action is, at least partially, associated with antioxidant stress and inhibition of NLRP3 inflammasome activation.

show abstract

Study on Antidepressant Activity of Pseudo-Ginsenoside HQ on Depression-Like Behavior in Mice

Cited by 19 publications

References 33 publications

Therapeutic Targets and Mechanism of Xingpi Jieyu Decoction in Depression: A Network Pharmacology Study

Therapeutic Targets and Mechanism of Xingpi Jieyu Decoction in Depression: A Network Pharmacology Study

PPARγ and Cognitive Performance

Liquiritin Alleviates Depression-Like Behavior in CUMS Mice by Inhibiting Oxidative Stress and NLRP3 Inflammasome in Hippocampus

Contact Info

Product

Resources

About